A retrospective analysis sought to determine the association between myeloproliferative neoplasms, MPN-directed therapy, and development of splanchnic vein thrombosis.
Although some red blood cell-related parameters used in the diagnosis of PV may be misleading in the setting of iron-deficiency, RBC count may be an effective biomarker for PV when combined with ESR.
This nonrandomized study enrolled more than 100 patients with essential thrombocythemia or polycythemia vera resistant to or intolerant of hydroxyurea to determine if interferon alfa-2a is effective in these patients.
Although extreme thrombocytosis occurs rarely, researchers were able to identify its underlying cause and potential prognosis for patients who develop the condition.
A systematic review of studies sought to determine the likelihood of myeloproliferative neoplasm subtypes based on patients’ genetic alterations.
A retrospective study sought to determine if treatment of myeloproliferative neoplasms with ruxolitinib may have nephroprotective effects.
A retrospective study compared disease progression and mortality rates in younger patients with MPNs vs historical controls of older patients with MPNs.
An analysis of responses to the 2017 Landmark Survey revealed that disease-burden symptoms of MPN is challenging for both patients with the disease and their physicians.
A study with more than 2000 patient-years follow-up, researchers found cytoreductive therapy was not as effective in patients with ET who have lower risk for thrombosis.
A phase 2 study compared ruxolitinib with best-available therapy as second-line treatment for patients with high-risk essential thrombocythemia or polycythemia vera who became intolerant of first-line therapy.
